Drug Trial Radar · NCT06500507
A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Jul 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Aug 30, 2024
Primary completion
Mar 31, 2026
Study completion Jan 31, 2027
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to characterize the safety of QLS4131 injection and to determine the recommended Phase 2 dose (RP2D) and to further evaluate the efficacy and safety of QLS4131 injection in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose.
Conditions
- Relapsed or Refractory Multiple Myeloma
Interventions
QLS4131 InjectionDrug
Participants confirming to the eligibility criteria will be assigned to 1 of the 9 dose groups (0.06/0.3/1 \~ 600 ug/kg, respectively) based on the sequence of inclusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended Phase 2 Dose (RP2D)Time frame: Approximately 2 years
- Incidence of adverse events(AEs)Time frame: Up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.